Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Graham Capital Management L.P.

Graham Capital Management L.P. trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 83.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,268 shares of the company's stock after selling 61,645 shares during the quarter. Graham Capital Management L.P.'s holdings in Pacira BioSciences were worth $231,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after buying an additional 70,307 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Pacira BioSciences by 5.1% in the fourth quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock worth $4,323,000 after buying an additional 11,149 shares in the last quarter. LPL Financial LLC bought a new stake in Pacira BioSciences in the fourth quarter worth $251,000. Finally, Norges Bank bought a new stake in Pacira BioSciences in the fourth quarter worth $2,405,000. 99.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Barclays boosted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Price Performance

PCRX stock traded down $0.32 during midday trading on Friday, reaching $25.75. The stock had a trading volume of 477,629 shares, compared to its average volume of 975,187. The company's fifty day simple moving average is $25.21 and its 200 day simple moving average is $22.73. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -12.68 and a beta of 0.56. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.64.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.